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KETEGANGAN SALUR DARAH, PENANDA KERADANGAN DAN 
‘ATHEROGENIC’ DALAM PENYAKIT KENCING MANIS SEMASA HAMIL 
ABSTRAK 
 
Kencing manis semasa hamil merupakan salah satu penyakit yang biasa dihidapi semasa 
kehamilan, dengan kadar 1-18% untuk semua kehamilan bergantung kepada populasi. 
Peningkatan ketegangan salur darah biasa berlaku pada pesakit kencing manis ‘Type 1’ 
dan ‘Type 2’ dan telah dilaporkan dalam banyak laporan kajian. Tahap ketegangan salur 
darah juga telah ditunjukkan dapat mengesan penyakit-penyakit jantung. Pemeriksaan 
tahap ketegangan salur darah dapat mengesan lebih awal penyakit-penyakit jantung dan 
seterusnya dapat membantu dalam megawal penyakit tersebut. Terkini, analisa 
gelombang denyutan dan halaju gelombang denyutan telah digunakan dan dibuktikan 
sebagai salah satu cara untuk mengukur tahap ketegangan salur darah yang tidak 
menyakitkan. Selain itu, penanda keradangan and ‘atherogenic’ juga boleh memberi 
kesan kepada fungsi salur darah dan ketegangan salur darah. Oleh sebab itu, kajian ini 
juga mengukur ‘tumor necrosis factor alpha’ (TNF-α), ‘high sensitivity C-reactive 
protein’ (hsCRP) and ‘plasminogen activator inhibitor-1’ (PAI-1) sebagai salah satu 
perimeter.  
    
Tujuan kajian ini dijalankan adalah untuk mengetahui samada pesakit yang menghidapi 
kencing manis semasa hamil mempunyai kaitan dengan peningkatan tahap ketegangan 
salur darah dan peningkatan penanda keradangan dan ‘atherogenic’ berbanding pesakit 




Kajian ini merupakan kajian secara rentas yang melibatkan 53 wanita hamil pada 
peringkat trimester ketiga kehamilan. Wanita hamil ini terdiri daripada 31 wanita dengan 
kehamilan yang normal dan 22 wanita dengan penyakit kencing manis semasa hamil. 
Pesakit dibahagikan kepada dua kumpulan ini berdasarkan keputusan ujian ‘75 g Ujian 
Air Gula yang Dimodifikasi (MOGTT)’. Pesakit diklasifikasikan sebagai penghidap 
kencing manis semasa hamil sekiranya tahap glukosa selepas mereka puasa sepanjang 
malam adalah lebih daripada 6.1 mmol/L dan/atau tahap glukosa selepas dua jam 
pengambilan air gula adalah lebih daripada 7.8 mmol/L. Tahap ketegangan salur darah 
dalam kajian ini diukur dengan menggunakan prinsipal analisa gelombang denyutan dan 
halaju gelombang denyutan menggunakan Sphygmocor. Analisa gelombang denyutan 
juga digunakan untuk mendapatkan bacaan bagi indeks augmentasi (AIx). Tekanan 
darah aortik, tekanan darah brakial, tekanan denyutan aortik, min bagi tekanan arterial, 
indeks jisim badan dan paras serum kolesterol secara total juga dicatatkan. Paras 
penanda keradangan (TNF- α and hsCRP)   dan ‘atherogenic’ (PAI-1) ditentukan 
menggunakan ELISA.  
 
Purata umur dan minggu kehamilan antara wanita hamil yang normal dan wanita yang 
menghidapi kencing manis semasa hamil tidak menunjukkan sebarang perbezaan yang 
signifikan (31.1±5.68 vs. 32.9±8.46 tahun; 29.0±2.43 vs. 29.6±1.54 minggu untuk 
masing-masing). Tahap glukosa semasa berpuasa dan selepas dua jam minum air gula 
adalah tinggi secara signifikan pada wanita yang menghidapi kencing manis semasa 
hamil (3.94±0.44 vs. 5.27±1.19 mmol/L, p<0.001; 5.68±1.10 vs. 9.66±1.76 mmol/L, 
p<0.001). Prinsipal halaju gelombang dan indeks augmentasi tidak berbeza secara 
signifikan antara wanita hamil secara normal dan wanita yang menghidapi kencing 
 xix 
 
manis semasa hamil. Walau bagaimanapun, tahap TNF-α, PAI-1 and hsCRP adalah 
tinggi secara signifikan pada wanita yang menghidapi kencing manis semasa hamil 
[TNF-α; 0.81 (0.15) vs. 0.72 (0.13) pg/ml, PAI-1; 54.48 (13.07) vs. 36.16 (15.58) ng/ml, 
hsCRP; 7.91 (1.16) vs. 6.70 (1.45) mg/L]. Tiada perbezaan yang signifikan antara 
kedua-dua kumpulan kajian bagi bacaan tekanan darah aortic dan brakial, min bagi 
tekanan darah arterial, indeks jisim badan dan paras serum kolesterol secara total. 
 
Paras penanda keradangan TNF-α dan hsCRP, dan penanda ‘atherogenic’ PAI-1 
meningkat pada wanita yang menghidapi kencing manis semasa hamil berbading wanita 
hamil secara normal yang mempunyai purata umur yang sama. Tiada perbezaan secara 
signifikan pada tahap ketegangan salur darah, iaitu prinsipal halaju gelombang dan 
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Gestational diabetes mellitus (GDM) is one of the common medical complications 
occurring during pregnancy, affecting approximately 1-18% of all pregnancies; 
depending on the population. Increased arterial stiffening has been demonstrated 
consistently in both Type 1 and Type 2 diabetes in a number of studies. Arterial stiffness 
has been shown to precede cardiovascular diseases. The assessment of arterial stiffness 
allows early detection of cardiovascular disease and may help in preventive strategies. 
Pulse wave velocity (PWV) and pulse wave analysis (PWA) are non invasive method 
used to assess arterial stiffness. Inflammatory and the atherogenic markers may 
influence vascular function and arterial stiffness. The objectives of this thesis were to 
determine whether gestational diabetes mellitus (GDM) is associated with increased 
arterial stiffness, inflammatory and atherogenic markers compared to age and gestational 
age matched controls. Inflammatory and atherogenic markers measured in this study 
include tumor necrosis factor alpha (TNF-α), high sensitivity C-reactive protein (hsCRP) 
and plasminogen activator inhibitor-1 (PAI-1) as a parameters.  
    
This is a cross sectional study involving 53 pregnant women in the early third trimester 
of pregnancy consisting of 31 women with normal pregnancy and 22 women with GDM. 
Subjects were divided based on the 75 g Modified Oral Glucose Tolerance Test 
(MOGTT) results, and considered as GDM if the fasting glucose level after an overnight 
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fast ≥ 6.1 mmol/L and/or the level after 2 hours of glucose intake ≥ 7.8 mmol/L. Arterial 
stiffness was assessed non invasively using the principles of PWA and carotid femoral 
PWV using the Sphygmocor device. PWA was used to obtain the parameter percent 
augmentation index (AI). Aortic blood pressure, brachial blood pressure, aortic pulse 
pressure, aortic mean arterial pressure, body mass index (BMI) and serum total 
cholesterol were also recorded. The inflammatory (TNF- α and hsCRP) and atherogenic 
(PAI-1) markers were measured using the principle of Enzyme-linked Imunosorbent 
Assay (ELISA).  
 
Mean ages and gestational ages for the control and GDM groups showed no significant 
differences (31.1±5.68 vs. 32.9±8.46 years; 29.0±2.43 vs. 29.6±1.54 weeks 
respectively). Fasting and two hours glucose levels were significantly higher in GDM; 
(3.94±0.44 vs. 5.27±1.19 mmol/L, p<0.001; 5.68±1.10 vs. 9.66±1.76 mmol/L, p<0.001). 
PWV and AIx were not significantly different between normal and GDM pregnancies. 
However, TNF-α, PAI-1 and hsCRP levels were significantly higher in GDM compared 
to controls [TNF-α; 0.81 (0.15) vs. 0.72 (0.13) pg/ml, PAI-1; 54.48 (13.07) vs. 36.16 
(15.58) ng/ml, hsCRP; 7.91 (1.16) vs. 6.70 (1.45) mg/l]. There were no significant 
differences between them for aortic and brachial BP, MAP, BMI and serum total 
cholesterol.   
 
In conclusion, the inflammatory markers TNF-α and hsCRP, and the atherogenic marker 
PAI-1 were elevated in GDM compared to age and gestational age matched controls. 























Pregnancy is the period during which a woman carries a developing fetus, normally in 
the uterus (Oxford University Press, 2007). Gestation is the period during which a 
fertilized egg cell develops into a baby that is ready to be delivered (Oxford University 
Press, 2007).  Gestational period normally lasts for 40 weeks and is divided into three 













 weeks. During this period, many changes and 
adaptations occur in the woman’s body such as cardiovascular, respiratory and 
endocrine systems to accommodate the needs of the mother and fetus. 
 
1.1 Physiological changes during pregnancy 
 
1.1.1 Cardiovascular changes 
a) Heart rate 
Maternal heart rate may increase as early as four weeks of gestation, with an 
approximate 20% increase seen by seven weeks of gestation (Campbell, 2000). This 
heart rate increase occurs as a response to falling systemic vascular resistance (Duvekot 




b) Blood pressure 
Blood pressure falls approximately 10% by seven to eight weeks of gestation (Clapp et 
al., 1988) due to peripheral vasodilatation (Phippard et al., 1986). Systemic vascular 
resistance decreases by 20% in the second trimester because of the hormonal influences 
of oestrogen and progesterone and it remains low until term (Campbell, 2000). In the 
supine position, the gravid uterus may compress the inferior vena cava leading to 
significant reduction in maternal mean arterial pressure.  
 
c) Central Haemodynamics 
Due to increase in blood volume during pregnancy, stroke volume increases by 20% as 
early as five weeks of gestation and continue to increase to 30% at the end of the second 
trimester (Campbell, 2000). Cardiac output begins to increase from five weeks of 
gestation because of increased heart rate and stroke volume. The cardiac output 
continues to increase to 40% by the end of first trimester and reaches 50% by term 
(Mabie et al., 1994).  
 
1.1.2 Hematological changes 
a) Blood volume 
Plasma volume increases up to 15% as early as the first trimester to as high as 50% in 
the second trimester. This condition is the direct result of maternal oestrogen (which 
increases plasma rennin) and progesterone (which increases aldosterone production) as 
well as fetal hormones such as dehydroepiandrosterone. These hormonal influences lead 
to sodium and water retention. During pregnancy, red cell volume decreases in the first 
trimester but increases to 30% above pre pregnancy levels by term (Campbell, 2000). 
 4 
 
The increase in red cell volume meets the extra oxygen demands of the mother and 
fetus. The normal range of hemoglobin in pregnancy is between 11- 12 g/dL. World 
Health Organization recommends iron supplementation if the level of hemoglobin is less 
than 11.0 g/dL. Hematocrit decreases by 15% at the second trimester of pregnancy. 
White cell count increases in pregnancy and the normal range of white cell count for 
pregnancy is between 5000- 15000/mm
3 
(Carlin and Alfirevic, 2008). The platelet count 
usually falls in pregnancy (O’Brien, 1976). Mild thrombocytopenia (100000- 
150000/mm
3
) is present in approximately 8% of pregnancies and has been termed 
‘gestational thrombocytopenia’ (Burrows and Kelton, 1990).   
 
b) Coagulation system 
In pregnancy, the circulating levels of factors VII, VIII, IX, X and XII, fibrinogen and 
von Willibrand factor increases, factor XI decreases, while prothrombin and factor V 
remain unchanged (Hellgren, 1996). The natural anticoagulants antithrombin III and 
protein C levels are unchanged or increase, and protein S levels falls (Hellgren, 1996). 
Fibrinolytic activity is known to decrease, mainly due to the marked increase in 
plasminogen activator inhibitors, PAI-1 and PAI-2 (Davis, 2000). The combination of 
all these changes increases the risk of thrombosis during pregnancy and puerperium 








1.1.3 Respiratory changes 
a) Mechanics of ventilation 
As the pregnancy progresses, the uterus expands upwards and changes the chest shapes. 
The lower ribs ‘flare’ due to looser ligaments under the influence of progesterone. The 
thoracic circumference increases by 8% (Contreras et al., 1991), and both the transverse 
and the anteroposterior diameters increase by 2 cm. These changes increase the chest 
excursion and lead to a 5 cm elevation of the diaphragm (Elkus and Popovich J, 1992).  
 
b) Ventilation 
During pregnancy, oxygen consumption increases by 30- 50 mL/min. Two- third of the 
increase meets additional maternal requirements (mainly the kidney) and one- third is 
for the developing fetus (Alaily and Carrol, 1978). The increase in oxygen consumption 
is associated with a 40% increase in ventilation secondary to a progressive rise in tidal 
volume of 200 ml (from 500 ml to 700 ml) (Cugell et al., 1953). Respiratory rate 
increases between 14- 15 breaths/min (Pernoll et al., 1975). Minute ventilation increases 
by approximately 40%, with tidal volume, from 7.5 L/min to 10.5 L/min (Spatling et al., 
1992). However, the reason for the ventilation increase is still unclear. Progesterone may 
play a role by lowering the threshold (Wilbrand et al., 1952) and/or increase the 
sensitivity (Skatrud et al., 1978) of the respiratory centre to carbon dioxide, or act 







1.1.4 Endocrine changes 
a) Progesterone   
Progesterone is mainly produced by the placenta. The level of progesterone increases 
during pregnancy. Progesterone mainly inhibits uterine smooth muscle contraction and 
decreases prostaglandin formation. These functions allow the fetus to grow with the 
expanding uterus. As progesterone levels increase, other smooth muscle in the body may 
also be affected, such as the lower esophageal sphincter, which results in increased 
heartburn and acid reflux, especially in the later stages of pregnancy. Progesterone also 
softens the cartilage and may be responsible for the commonly occurring hip and pubic 
bone pain. This hormone also causes tenderness in the breasts and the bloated feeling 
experienced by many women throughout pregnancy (Catalano, 1991). 
 
b) Oestrogen 
Oestrogen level also increases during pregnancy and are produced primarily by the 
placenta. Oestrogen is crucial to the reproductive success of woman. Oestrogen has a 
major role during pregnancy of building tissue. One role of oestrogen during pregnancy 
is to regulate the production of progesterone over the full term. As oestrogen is produced 
by the placenta, progesterone production is stimulated and regulated. Oestrogen is a 
major factor in the increased size of the uterus and thickening of the uterine wall. During 
the pregnancy, the uterus increases in size to accommodate the developing pregnancy. 
Oestrogen is responsible for increased blood, lymphatics and nerve supply to the uterus, 
and throughout the body. The considerable increase in the number and size of vessels in 
the uterine vascular bed causes a decrease in the uterine vascular resistance. As a result, 
blood flows to and from the uterus more freely. Prolactin, the hormone that allows for 
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postpartum lactation, also increases throughout pregnancy, and its production is thought 
to be stimulated by the increasing levels of oestrogens (Sembulingam et al., 2001).  
 
c) Insulin 
Insulin is a natural hormone produced by the beta cell of the islets of Langerhans in the 
pancreas and plays a role in controlling the level of glucose in the blood. Cells cannot 
utilize glucose without insulin. The failure of insulin production or reduced insulin 
sensitivity leads to diabetes mellitus. The diminished ability of cells to respond to the 
action of insulin in glucose uptake from the bloodstream into muscle and other tissues is 
called insulin resistance. During pregnancy, insulin sensitivity declines by 50% in the 
third trimester (Catalano, 1991), which may be mediated by increases in various 
hormones such as oestrogen, progesterone, β-human chorionic gonadotrophin, human 
placental lactogen, growth hormone and cortisol (Ryan et al., 1988).             
                                                                                                                                                                                                                                                                                                                  
1.2 Diabetes mellitus  
Diabetes mellitus affects over 150 million people worldwide and this number is 
expected to double by the year 2025 (Genuth et al., 2003). Diabetes mellitus is a chronic 
disease characterized by insulin deficiency, resulting in glucose intolerance. Other than 
diabetes mellitus, the word diabetes is also used for another disease, which is diabetes 
insipidus. As diabetes insipidus is rare, diabetes mellitus is usually known simply as 
diabetes. Diabetes mellitus can be divided into insulin dependent diabetes mellitus 
(IDDM) or Type 1 diabetes mellitus, and non insulin dependent diabetes mellitus 
(NIDDM), also known as Type 2 diabetes mellitus. Type 1 diabetes mellitus is the result 
of an absolute deficiency in insulin secretion due to autoimmune destruction of the β 
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cells of the pancreas. Type 2 diabetes mellitus is most commonly due to tissue resistance 
to insulin action and relative insulin deficiency. Gestational diabetes mellitus (GDM) is 
impaired glucose tolerance that occurs during pregnancy. 
 
Insulin is a protein that regulates the transport of glucose from the plasma into the 
cytoplasm of cells to provide energy for body use. Usually after a large meal, insulin 
level in the blood increases, this induces the tissues to take up and store glucose. 
Without enough insulin, glucose builds up in the bloodstream instead of going into the 
cells. Cells of the body are unable to use this glucose for energy despite high levels in 
the bloodstream. This is detected by the central satiety centre, leading to a sense of 
hunger. In addition, the high level of glucose in the renal tubule causes osmotic diuresis 
and manifest as increase in urination. This leads to decrease in extracellular volume and 
excessive thirst.  
 
The symptoms of diabetes mellitus include frequent urination, excessive thirst, extreme 
hunger, increased fatigue, unusual weight loss, irritability, and blurred vision. Diabetes 
mellitus is often linked to other chronic diseases such as atherosclerosis, which leads to 
cardiovascular diseases such as stroke and hypertension, retinopathy, glaucoma, 
cataracts, gangrene, and kidney failure.  
 
1.2.1 Type 1 Diabetes Mellitus   
Type 1 diabetes mellitus is also known as juvenile or insulin dependent diabetes 
mellitus. It begins more commonly in childhood or adolescence. Only approximately 
10% of type 1 diabetes patients were above 60 years old.  
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For type 1 diabetes, patients usually depend on exogenous insulin. These patients may 
require several injections of different types of insulin during the day to keep their blood 
sugar levels within a normal range. There are two conditions that may lead to Type 1 
diabetes that are firstly, insufficient insulin production because of pancreas damage 
particularly at beta cell of Islet of Langerhans and secondly, abnormal form of insulin 
produced. 
 
1.2.2 Type 2 Diabetes Mellitus 
Type 2 diabetes mellitus is the more common type of diabetes, accounting for 85-90% of 
all those diagnosed with diabetes mellitus. This form of diabetes normally occurs in 
adults and is also known as non insulin dependent diabetes mellitus (NIDDM). Type 2 
diabetes mellitus is a chronic metabolic syndrome that occurs due to insulin resistance. 
This leads to hyperglycaemia (increased blood sugar levels) and deranged metabolism of 
carbohydrate, fats and proteins. These abnormalies result in decreased glucose transport 
into muscle, increased liver glucose production, and increased breakdown of fat.  
 
Obesity and aging are common risk factors for type 2 diabetes. The incidence of type 2 
diabetes increases with age. Most patients develop type 2 diabetes mellitus after 40 years 
of age. Genetics is another risk factor of type 2 diabetes. Genetic predisposition plus 
unhealthy lifestyle such as excess intake of fat and sugar or inadequate physical activity 






1.2.3 Gestational diabetes mellitus (GDM) 
Gestational diabetes mellitus (GDM) is defined as glucose intolerance resulting in 
hyperglycemia of variable severity with onset or first recognition during pregnancy 
(Metzger et al., 1998). GDM usually appears between the 24th to 28th gestational 
weeks. The blood glucose level usually will return to normal after delivery. GDM is one 
of the most common medical complications occurring during pregnancy (Metzger et al., 
1998). The prevalence of GDM may range from 1%-4% worldwide depending on the 
population and the method of screening (ADA, 2000). Malaysian prevalence of GDM 
was reported to be approximately 18.3% (Idris et al., 2007). 
 
Gestational diabetes mellitus occurs when the body is unable to make effective use of 
insulin during pregnancy (Chandrasoma et al., 1995). According to Chandrasoma et al. 
(1995), gestational diabetes is pathophysiologically similar to non insulin dependent 
diabetes mellitus. GDM carry risks for both the fetus and the mother. The high blood 
glucose levels pass through the placenta, causing the baby to also have high blood 
glucose levels. The baby’s pancreas will respond by producing additional insulin to 
lower the blood glucose. More glucose will be converted to energy than the fetus’ needs, 
and the extra energy is stored as fat, causing macrosomia (large babies), which is one of 
the common effects of GDM. The newborn may also experience hypoglycemia (shortly 
after birth), breathing problems and prolonged jaundice. These babies experience 





On the mother’s side, women with GDM have a problem of obstructed labor due to large 
babies. Obstructed labor leads to other consequences which include ceasareans delivery, 
birth injuries to the mother and newborn and low apgar scores. Cardiovascular 
complications such as pregnancy induced hypertension and preeclampsia also occur 
more frequently in GDM compared to non GDM pregnancies (Paradisi et al., 2002).  
 
Women with GDM have increased risk of subsequently developing diabetes mellitus late 
in life. According to O’Sullivan et al. (1984), one–third to one-half of women with a 
history of GDM will develop type 2 diabetes mellitus within three to five years, and 
70% will develop type 2 diabetes mellitus if followed up for more than ten years. 
Metzger et al. (1993) also reported that women with history of GDM have a risk 
between 18-50% of developing type 2 diabetes within 5 years following pregnancy.   
 
Management of GDM can be divided into four main aspects, which include monitoring, 
non-pharmacological interventions, pharmacological intervention and obstetrics 
management. Essentially, maternal metabolic progression should be monitored. Daily 
self-monitoring of blood glucose is very important prior to the follow up visits (ADA, 
2000). Glucose level should be as near as possible to normal range: fasting plasma 
glucose level should be < 5.3 mmol/L; post-prandial levels at first and second hour 
should be < 7.8 mmol/L and < 6.7 mmol/L respectively (Metzger and Coustan, 1998). 
Fetal monitoring should be performing routinely which include maternal monitoring of 
fetal movement, cardiotocography and ultrasonography. The presence of fasting 
hyperglycemia >5.8 mmol/L may be associated with an increased risk of intrauterine 
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fetal death during the last 4-8 weeks of pregnancy (ADA, 2000), thus the importance of 
monitoring maternal blood glucose levels and fetal condition.  
 
Secondly, non pharmacological therapy includes diet and exercise. Nutritional 
counseling is very important in patients with GDM. An experienced and qualified 
dietician should perform the counseling. It is important to provide adequate calories for 
maternal needs, fetal growth and adequate weight gain while avoiding hyperglycemia 
and ketosis (ADA, 2000). Exercise is one of the important steps in the management of 
GDM. Exercise has been reported to improve glycaemic control in patient with GDM 
(Bung et al., 1991).  
 
Pharmacology therapies may include use of insulin and oral hypoglycemic agents 
(OHAs). Insulin should be considered when the diet and exercise are inadequate to 
maintain optimal level of blood glucose. Insulin therapy should be initiated if the fasting 
blood sugar is more than 5.3 mmol/L or two-hour post prandial level is more than 6.7 
mmol/L (ADA, 2000). Human insulin should be the insulin of choice. OHAs is not 
recommended in pregnancy because of the potential side effects to the fetus, particularly 
that of hypoglycemia and fetal anomalies (ADA, 2000).  
 
Another component to GDM management is obstetric management. GDM patients 
should be reassessed after at least 6 weeks post delivery (ADA, 2000). If sugar levels are 
normal post partum, these patients should be monitored at least 3 yearly. They should 
also be informed of their risk of developing type 2 diabetes and the potential symptoms 
(Gabbe et al., 1998).           
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Most research that study the effect of GDM on vascular function, inflammatory and 
metabolic markers focused on women with previous history of GDM and compare them 
to those with history of uncomplicated pregnancy. Normoglycemic women with a 
history of GDM have been reported to have increased insulin resistance and decreased 
endothelium-dependent vasodilatation compared to women who had a history of 
uncomplicated pregnancy (Kousta et al., 2003). Heitritter et al. (2005) reported that 25 
nondiabetic women with previous gestational diabetes showed increased biochemical 
and hemodynamic markers of cardiovascular disease compared to 23 nondiabetic 
women without a history of gestational diabetes. Subjects with a history of GDM also 
had significantly higher diastolic blood pressure and mean arterial pressure compared to 
women with no history of GDM. Metabolic parameters such as fasting blood glucose, 
triglyceride, and homeostasis model assessment (HOMA) were also significantly higher 
in women with history of GDM. Compared to the control group, women with a history 
of GDM had higher levels of inflammatory markers (C-reactive protein, interleukin-6, 
and plasminogen activator inhibitor-1) and lower levels of adiponectin. These indicate 
that women with prior GDM have subclinical inflammation, are hypoadiponectinemia, 
and display early vascular dysfunction, all of which may increase their risk of 









1.3 Arterial compliance and arterial stiffness 
 
1.3.1 Structure of the arteries 
The circulation of the blood from the heart passes through elastic arteries, muscular 
arteries, arterioles, capillaries, venules and veins. All arteries comprised of three distinct 
layers, which are the tunica intima, tunica media and tunica externa. The outermost layer 
is known as the tunica externa or tunica adventitia, and is composed of connective 
tissue. Inside this layer is tunica media, which is made up of smooth muscle cells and 
elastic tissues. The tunica intima, or innnermost layer, consists of a layer of endothelial 
cells separated from the inner layer by a narrow layer of connective tissues. This layer is 
in direct contact with the blood flow. Lastly, the hollow internal cavity in which the 
blood flows is called the lumen.  
 
The aorta and arteries have more elastic tissues while the arterioles have more smooth 
muscles. The arterial branches become narrower and their walls become thinner when 
reaching the periphery from the heart. The diameters of arteries arising from the aorta 
are about 25 mm and in the arterioles is 0.3 mm. The capillaries have diameter of about 
five to eight micrometer (Sembulingan et al., 2000). 
 
1.3.2 Function of the arteries 
The blood flows through two divisions of the circulatory system which is the systemic 
circulation and pulmonary circulation. Systemic circulation starts when the oxygenated 
blood is pumped from the left ventricle and passes through a series of blood vessels of 
the arterial system until it reaches the tissues. The blood vessels of the arterial system 
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are the aorta, arteries (large and small arteries) and arterioles. The arterioles branch into 
capillaries. The capillaries are responsible for exchange of various substances between 
blood and the tissues. The deoxygenated blood enters the venous system and returns to 
the right atrium of the heart. The venous system consists of venules, veins and the vena 
cava. Pulmonary circulation is the circulatory of blood from the right ventricle to the 
lungs through the pulmonary artery. Exchange of gases occurs in the lungs between 
blood and the alveoli. The oxygenated blood then returns to left atrium through the 
pulmonary veins (Sembulingam et al., 2000).  
 
In both circulatory systems, arteries play an important role for blood distribution. Large 
arteries branching off the aorta distribute blood flow to specific organs. Examples of 
large arteries are the carotid, mesenteric and renal arteries. Once a large artery reaches 
the organ it branches into smaller arteries that distribute blood flow within the organ. 
Small arteries and arterioles are involved in the regulation of arterial blood pressure as 
well as blood flow within the organ (Chandrasoma et al., 1991). 
 
The arterial tree also function to cushion the pulsation generated by the heart so that the 
capillary blood flow is continuous. In the arterial system, the cushioning and conduit 
functions are combined. This combination of functions leads to pressure wave travel and 







1.3.3 Arterial compliance and arterial stiffness 
Arterial compliance is an index of vascular health and is defined as the ability of the 
arterial to expand due to a given change in the arterial pressure (O’Rourke and Mancia, 
1999). Therefore arterial compliance is pressure dependent and varies inversely with the 
level of mean arterial pressure within the physiological range. The measurement of 
arterial compliance has received increased attention because of its association and 
predictor value for cardiovascular diseases (Havlic et al., 2003, Laurent et al., 2001).    
 
Arterial stiffness is a dysfunctional property of the arterial circulation that precedes the 
development of clinical cardiovascular disease (Laurent et al., 2001). Arterial stiffness is 
determined by functional and structural components related to the intrinsic elasticity of 
the artery. Elastic property is the ability of the artery to stretch when a stress is given and 
cope with a given stress to return to its original shape when excess stress is removed. 
The stiffer the artery, the lesser its compliance and vice versa.  
 
Arterial stiffness is an independent predictor of cardiovascular morbidity and mortality 
(Hansen et al., 2006, Laurent et al., 2001). Arterial stiffness is a major contributor to 
atherosclerotic and small vessel disease and thus to occurrence of stroke, myocardial 
infarction, and renal failure. Laurent et al., (2000) reported a significant association of 
aortic stiffness assessed using the the parameter pulse wave velocity with cardiovascular 
mortality in patients with cardiovascular diseases [odd ratio (OR) of 1.34 with every 5 
m/s increment in PWV]. Hansen et al. (2006) stated that for each 1-SD increment in 




Arterial stiffness has been shown to be increased in pregnant women with pregnancy 
induced hypertension, preeclampsia, and diabetic patients (Tihtonen et al., 2006, 
Macaedo et al. 2008, Khalil et al., 2009, Robb et al., 2009, Veikko et al., 1995, 
Lehmann et al., 1992). When this study was planned and started, there were no studies 
conducted to determine if GDM is associated with increased arterial stiffness, thus this is 
one of the objectives of this study. In our study, arterial stiffness will be measured using 
the parameters carotid femoral pulse wave velocity and augmentation index derived 
from pulse wave analysis. 
 
1.3.4 Factors affecting arterial stiffness 
Arterial compliance and arterial stiffness has been reported to be affected by several 
factors such as age (Anette et al., 2008), gender (Maxwell, 1998), physical activity 
(Tanaka et al., 2000), obesity (Satoru et al., 2009), smoking (Nirandeep et al., 2006), 
hypertension (Benetos et al., 1997), diabetes mellitus (Lehmann et al., 1992), 
hypercholesterolemia (Wilkinson et al., 2002) and genetic factors (Mitchell et al., 2005). 
Some of the stated factors are described below. 
 
a) Age 
Increased stiffness of the arteries is commonly associated with advancing age (Anette et 
al., 2008). With ageing, the aorta and central elastic arteries dilate and stiffen. Dilatation 
and stiffening are most marked in the proximal aorta and its major branches such as the 
brachiocephalic, carotid and subclavian arteries. Increased arterial stiffening with age is 
apparent as an increase in pulse wave velocity (O’Rourke, 2007). A typical value of 
carotid femoral PWV in a 20 years old is approximately 5 m/s while in 80 years old is 
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approximately 12 m/s (2.4 fold increase over 60 years) (Laurent et al., 2006). Structural 
and functional changes associated with aging may impair the compliance of the arterial 
circulation. In terms of vascular functional changes, altered regulation of vascular tone 
due to reduced presence or production of endothelium derived relaxing factors (EDRF) 
could increase arterial stiffness. Endothelial release of nitric oxide has been shown to be 
impaired with aging (Gerhard et al., 1996). Reduced nitric oxide would not only produce 
vasoconstriction, which increases arterial stiffness, but would also promote vascular 
smooth muscle growth that can lead to the increase of arterial stiffness.  
 
Structurally, the thickening of the intima and media layers of the vascular wall play a 
role in the increased stiffness seen with ageing. Nagai et al. (1998) reported increased 
thickness of intima-media with increasing age. With advancing age, the distensibility of 
an artery decrease in proportion to the increase in collagen in the media, and to a lesser 
extent in the intima. Increased pulse wave velocity has been linked to structural 
alterations in the vascular media which include increased collagen, reduced elastin 
content, elastin fractures and calcifications (Elliott et al., 1994). In large arteries, aging 
results in progressive deposition of calcium salts, fraying and fragmentation of elastin, 
an increase in the number and cross linking of collagen fibers that alter the compliance 
characteristics of the vessel wall (Robert et al., 1996).  








Arterial compliance is greater in females compared to males of the same age before the 
onset of menopause (Maxwell, 1998). Oestrogen receptors were demonstrated in aorta of 
dogs (Horowitz and Horowitz, 1982), rats (Lin and Shain, 1985), rabbits (Perrot-
Applanat et al., 1988), baboons (Lin et al., 1986), in smooth muscle cells isolated from 
the rat (Lavigne et al., 1995) and human (Losordo et al. 1994) coronary arteries. 
Limited- capacity, high- affinity binding sites for oestrogen were also reported in 
cytosols isolated from endothelium of rabbit (Colburn and Buonassisi, 1978), and bovine 
aorta (Bayard et al., 1995), suggesting that the vascular endothelium is also oestrogen- 
sensitive. The presence of oestrogen receptors showed the ability of oestrogen binding in 
the endothelium, which is essential to a change in the loading conditions on the elastin 
and collagen fibers. Oestrogen may alter vessel wall loading conditions through 
vasodilatation by mechanisms that include potentiation of endothelial- dependent 
vasodilatation mediated by nitric- oxide (Lieberman et al., 1994, Sudhir et al., 1995). 
Vascular dilations transfers vascular wall stress from the collagen fibers, resulting in a 
more compliant vasculature.  
 
c) Physical activity 
Regular aerobic exercise is proven to reduce central arterial stiffness associated with 
ageing (Tanaka et al., 2000). Regular physical activity such as aerobic exercise is known 
to be an important component of prevention and treatment of cardiovascular diseases 
(Hodes et al., 1995). Boreham et al. (2004) reported that cardiorespiratory fitness and 
sports- related physical activity were inversely associated with arterial stiffness in young 
adults. Sports related physical activity score in men and women was shown to be 
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inversely and significantly associated with pulse wave velocity (PWV) of the 
aortodorsalis pedis, meaning improved aortic stiffness with increasing physical activity. 
Adjustment for other lifestyle variables (age, sex, height, weight, mean arterial pressure, 
smoking, and alcohol consumption) and body fat did not attenuate the strength of 
association between physical activity and arterial stiffness.  
  
d) Obesity 
Obesity is associated with increased CVS risk and arterial stiffness. Kodama et al. 
(2009) reported that increased body mass index and adiposity are associated with arterial 
stiffening. However, the pathophysiology mechanisms that link obesity to arterial 
stiffening is still largely unknown. One of the mechanisms that could be involved is 
increased circulating proinflammatory cytokines and leptin (Singhal et al., 2002). Leptin 
has been shown to induce oxidative stress in endothelial cells (Oda et al., 2001). Oda et 
al. (2001) showed that activator of leptin receptors stimulates smooth muscle cell 
proliferation and migration, whereas prolonged treatment with leptin has been shown to 
increase vascular cell calcification (Parhami et al., 2001). Reduced nitric oxide would 
not only produce vasoconstriction, which increases arterial stiffness, but would also 
promote vascular smooth muscle growth which can lead to increase in arterial stiffness.  
 
e) Smoking 
Smoking leads to alterations in hemostatic factors, endothelial function and blood lipids. 
There is evidence that compliance of both large and medium- sized arteries decrease 
immediately after the smoking of one cigarette (Kool et al., 1993). Nirandeep et al. 
(2006) showed significantly increased systemic augmentation index [(median 17.25 % 
 21 
 
vs. 11.75 %)] (a parameter for arterial stiffness) using the SphygmoCor device in 50 
smokers (who smoked at least ten cigarettes per day) compared to 50 non smokers (p= 
0.004). Higher percent augmentation index indicates increased arterial stiffness. This 
suggested that smoking ten cigarettes per day is enough to induce marked endothelial 
dysfunction. This finding is supported by Barua et al. (2002), who found that nitric 
oxide (NO) production and eNOS expression and activity were all impaired both in light 
and heavy smokers. Reduced NO would promote vascular smooth muscle growth which 
leads to increased arterial stiffness.  
 
f) Hypercholesterolemia  
It has been reported that asymptomatic hypercholesterolemia substantially alters 
endothelial function, leading to decreased relaxation of arteries (Wilkinson et al., 2002). 
Wilkinson et al. (2002) showed significant rises of augmentation index (24.8% ± 11.3% 
vs. 15.6% ± 12.1%; p<0.001) and central pulse pressure (37 ± 11 mm/Hg vs. 33 ± 10 
mm/Hg; p=0.028) in 68 subjects with hypercholesterolemia (≥6.5 mmol/L) compared to 
68 normocholesterolemic patients. The same authors, had previously shown 
hypercholesterolemia to be strongly associated with endothelial dysfunction and reduced 
nitric oxide bioavailability (Wilkinson et al., 1998), which leads to arterial stiffening.  
 
g) Hypertension  
Stiffening of large arteries may be both a cause and a consequence of hypertension. As 
arterial pressure rises, arterial compliance decreases. Hypertension may produce arterial 
stiffening by both functional and structural mechanisms (Nichlos et al., 1998). Elevated 
blood pressure over time can lead to structural changes which influence mainly the 
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elastic arteries, responsible for the cushioning function of the arterial tree. These 
structural changes are due to vascular remodeling and hypertrophy associated with 
hypertension itself (Nichlos et al., 1998). Functionally, an initial elevation in blood 
pressure may establish a feedback mechanism. This increases arterial stiffness by 
increased cylic acids without any structural change. Elevation of blood pressure may 
consequently lead to vascular hypertrophy and hyperplasia, collagen deposition and 
atherosclerosis, thus resulting into elevation of arterial stiffness (Arnett et al., 2000). 
 
h) Diabetes mellitus 
Increased arterial stiffening has been demonstrated consistently in both Type 1 and Type 
2 diabetes mellitus (Aoun et al., 2001). The study by Aoun showed significantly 
increased pulse wave velocity and aortic pulse pressure in diabetic patients compared to 
non-diabetic patients. Lehmann et al. (1992) showed increased aortic stiffness in both 
Type 1 (n=25) and Type 2 (n=25) diabetes mellitus subjects using the non invasive 
Doppler ultrasound technique. Fujii et al. (1997) showed that hyperinsulinemia as 
assessed by an oral glucose tolerance test (OGTT) is associated with early 
atherosclerosis in normotensive, nondiabetic men. High insulin resistance causes 
upregulation of angiotensin II type 1 receptor (AT1) (Nickening et al., 1998) and may be 
the cause of stiffness in diabetes mellitus. They also reported that elevated levels of 
insulin result in overexpression of vascular AT1 receptor (Nickening et al., 1998). Dubey 
et al. (1998) reported that angiotensin II (Ang II) is a potent mitogen for smooth muscle 
cells in the presence of insulin. These actions were inhibited by AT1 but not AT2 
receptor antagonists. Thus in conditions where insulin levels are increased, the 
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exaggerated effects of Ang II on the vessel could aid in the development of arterial 
stiffness.  
 
1.4 Measurement of arterial stiffness  
There are several methods that can be used to assess arterial stiffness. Common non 
invasive parameters used to assess arterial stiffness include performing the pulse wave 
velocity (PWV), augmentation index (AI) and magnetic resonance imaging (MRI). In 
this study, PWV and AI were used to assess arterial stiffness in the study subjects. The 
MRI was not used as it is a very expensive equipment and not available for us to use.  
 
1.4.1 Pulse Wave Velocity (PWV) 
The velocity of pulse waveform along a stretch of artery is dependent on the stiffness of 
the artery along which the pulse is travelling. The velocity is slower in a compliant 
stretch of artery. Higher values of PWV correspond to a higher arterial stiffness. Serial 
measurements of PWV in a section of artery will indicate the magnitude of change in 
arterial compliance / stiffness in that section of artery. Carotid femoral PWV is a well 
established and non- invasive method to assess arterial stiffness (Lim et al., 2004, 
Pannier et al., 2002 and Wilkinson et al., 1998). It is recommended as one of the best 
methods for measuring arterial stiffness (O’Rourke et al., 2002). Pulse wave velocity 
can be measured in various segments of the arterial circulation such as carotid-femoral, 
carotid- radial and brachial- ankle. Carotid femoral pulse wave velocity was used in the 
current study. Carotid femoral pulse wave velocity gives the velocity of the pulse wave 
travel along the carotid- femoral segment by calculating the time delay between the 
pulse pressure waves at the two sites. The time taken for the arterial pulse to propagate 
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from the carotid to the femoral artery is divided from the distance between the two sites, 
which is determined by superficially by measuring the distance between the carotid and 
femoral pulsations.  
 
Pulse wave velocity and pulse wave analysis has been recently used to assess arterial 
stiffness in pregnancy. Macedo et al. (2008) showed significant difference in PWV 
between pregnant women (n=193), with gestational ages between 11-41 weeks, and 
nonpregnant controls (n=23), matched for age and height. Applanation tonometry was 
used to assess PWV. They found that normal pregnancy is associated with a reduction in 
central blood pressure and arterial stiffness. Compared to nonpregnant controls, pregnant 
women had lower mean arterial pressure (85±8.9 mmHg vs. 81.1±7.2 mmHg), central 
systolic blood pressure (103±11 mmHg vs. 96±8 mmHg), central diastolic blood 
pressure (71±9 mmHg vs. 67±7 mmHg), and augmentation index (19±11% vs. 4±12%). 
The augmentation index decreased significantly with gestation reaching its nadir at 
midpregnancy (p=0.001). The difference in augmentation index (between pregnant and 
non pregnant women) was present even after adjusting for known determinants of 
augmentation index such as maternal age (p<0.001), heart rate (p<0.001) and mean 
arterial blood pressure (p<0.001). However in this study, pulse wave velocity (carotid- 
radial and carotid- femoral) became not significant between pregnant and non pregnant 
women after adjustments for maternal age and mean arterial pressure. 
 
Mersich et al. (2005) showed a reducing trend of aortic PWV throughout pregnancy. 
Aortic PWV was gradually reduced during pregnancy from 6.2 m/s at first trimester to 
5.4 m/s at third trimester, then increased in the post partum period to 6.7±0.2 m/s. PWV 
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has also been used to assess the effect of diseases on arterial stiffness in pregnancy. In a 
study using 16 patients with pregnancy induced hypertension (PIH), PWV was shown to 
increase proportionally to the gestational age (Oyama-Kato et al., 2006). In his study, 
the predictive value of both PWV and blood pressure for developing PIH is higher than 
the value of blood pressure alone, suggesting the usefulness of measuring PWV to 
predict PIH. The trend of increasing PWV with gestational ages in PIH as shown by 
Oyama et al. (2006) was in contrast to the PWV changes in normal pregnancy as 
reported by Macaedo et al. (2008).  
 
Hu et al. (1998) stated that women with previous gestational diabetes mellitus (pGDM) 
(n=17) showed evidence of increased wall stiffness in the common carotid artery and a 
lower maximum incremental velocity of the pulsatile vessel diameter change in both 
aorta and carotid artery compared with controls (n=20). That study assessed the elastic 
properties in the large arteries using ultrasonic scanner. They found that the elastic 
modulus and the stiffness index of the carotid artery were higher in the pGDM. In aorta; 
pulse amplitude of the diameter (AD) [0.91 (0.47-1.58) mm vs. 1.06 (0.87-1.659) mm] 
and maximum incremental velocity of the diameter during the systolic phase (MIV) [32 
(146-58.6) mm vs. 45.2 (31.4-77.3) mm] were significantly lower in pGDM. In the 
common carotid artery; MIV [11.8 (5.5-19.3) mm vs. 13.9 (8.1-24.8) mm], elastic 
modulus [0.83 (0.58-1.77) vs. 0.70 (0.47-0.96)] and stiffness index [6.6 (54-12.7) vs. 6.2 
(4.48.3)] were significantly different between pGDM and controls. Stiffness index of the 
aorta was significantly higher in pGDM. Thus, this study showed asymptomatic women 
with history of GDM have abnormal vascular function compared to women without 
history of GDM (Hu et al., 2005).   
